Literature DB >> 17258689

Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

Marie-Alice Meuwis1, Marianne Fillet, Pierre Geurts, Dominique de Seny, Laurence Lutteri, Jean-Paul Chapelle, Vincent Bours, Louis Wehenkel, Jacques Belaiche, Michel Malaise, Edouard Louis, Marie-Paule Merville.   

Abstract

Crohn's disease and ulcerative colitis known as inflammatory bowel diseases (IBD) are chronic immuno-inflammatory pathologies of the gastrointestinal tract. These diseases are multifactorial, polygenic and of unknown etiology. Clinical presentation is non-specific and diagnosis is based on clinical, endoscopic, radiological and histological criteria. Novel markers are needed to improve early diagnosis and classification of these pathologies. We performed a study with 120 serum samples collected from patients classified in 4 groups (30 Crohn, 30 ulcerative colitis, 30 inflammatory controls and 30 healthy controls) according to accredited criteria. We compared protein sera profiles obtained with a Surface Enhanced Laser Desorption Ionization-Time of Flight-Mass Spectrometer (SELDI-TOF-MS). Data analysis with univariate process and a multivariate statistical method based on multiple decision trees algorithms allowed us to select some potential biomarkers. Four of them were identified by mass spectrometry and antibody based methods. Multivariate analysis generated models that could classify samples with good sensitivity and specificity (minimum 80%) discriminating groups of patients. This analysis was used as a tool to classify peaks according to differences in level on spectra through the four categories of patients. Four biomarkers showing important diagnostic value were purified, identified (PF4, MRP8, FIBA and Hpalpha2) and two of these: PF4 and Hpalpha2 were detected in sera by classical methods. SELDI-TOF-MS technology and use of the multiple decision trees method led to protein biomarker patterns analysis and allowed the selection of potential individual biomarkers. Their downstream identification may reveal to be helpful for IBD classification and etiology understanding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17258689     DOI: 10.1016/j.bcp.2006.12.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  41 in total

1.  Comparative proteomics analysis of serum proteins in ulcerative colitis patients.

Authors:  Nan Li; Xueming Wang; Yuefan Zhang; Junshan Zhai; Tuo Zhang; Kaihua Wei
Journal:  Mol Biol Rep       Date:  2011-12-24       Impact factor: 2.316

2.  Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery.

Authors:  Manuela G Neuman
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

Review 3.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

Review 4.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

5.  Platelet factor 4 is a biomarker for lymphatic-promoted disorders.

Authors:  Wanshu Ma; Hyea Jin Gil; Noelia Escobedo; Alberto Benito-Martín; Pilar Ximénez-Embún; Javier Muñoz; Héctor Peinado; Stanley G Rockson; Guillermo Oliver
Journal:  JCI Insight       Date:  2020-07-09

Review 6.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 7.  Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.

Authors:  Muriel De Bock; Dominique de Seny; Marie-Alice Meuwis; Jean-Paul Chapelle; Edouard Louis; Michel Malaise; Marie-Paule Merville; Marianne Fillet
Journal:  J Biomed Biotechnol       Date:  2009-12-06

Review 8.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

9.  Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD.

Authors:  Ellen J Scherl; Ernest G Seidman; Douglas C Wolf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

Review 10.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.